Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.38 |
| ▸ | MAG | P20916 | 11/20 | 0.37 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.35 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26554564 | 0.85 | SIGLEC7 (0.53) | SIGLEC7MAGSELE | |
| SCHEMBL24191529 | 0.82 | SIGLEC7 (0.55) | SIGLEC7MAGSELE | |
| SCHEMBL24191630 | 0.82 | SIGLEC7 (0.55) | SIGLEC7MAGSELE | |
| SCHEMBL26554524 | 0.81 | SIGLEC7 (0.49) | SIGLEC7MAGSELE | |
| SCHEMBL26562232 | 0.77 | MAG (0.37) | SIGLEC7MAGSELE | |
| SCHEMBL19726164 | 0.72 | SIGLEC7 (0.58) | SIGLEC7MAGSELE | |
| SCHEMBL17447128 | 0.72 | SIGLEC7 (0.49) | SIGLEC7MAGSELE | |
| SCHEMBL26554536 | 0.72 | SIGLEC7 (0.61) | SIGLEC7MAGSELE | |
| SCHEMBL26554496 | 0.71 | SIGLEC7 (0.54) | SIGLEC7MAGSELE | |
| SCHEMBL30540287 | 0.71 | SIGLEC7 (0.48) | SIGLEC7MAGENGASE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330248-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330248-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE | STING1, CGAS, TLR9 | SIGLEC7 141/4885MAG 1875/4885ENGASE 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.